Recombinant Mouse Cd70 protein, Fc-tagged, APC labeled

• Cat.No.: Cd70-972MA
• Product Overview: Recombinant Mouse Cd70 protein, Fc-tagged was Conjugated with NH2-Reactive APC(Allophycocyanin).

Specification

• Description: NH2-Reactive Allophycocyanin is used for antibody conjugation for immunostaining and cellular proteins for tracing. NH2-Reactive Allophycocyanin has succinimidyl ester groups, and can easily make a covalent bond with amino groups of protein without any activation process.
• Source: HEK293
• Species: Mouse
• Tag: Fc
• Form: Liquid in sterile PBS buffer pH 7.4 (may contains tiny amount of reaction buffer and Allophycocyanin).
• Endotoxin: <1EU/ug by LAL method.
• Stability: Sample is stable for at least 12 months when stored at -20 to -80°C from date of manufacture. For longer storage, add equal volume of glycerol to the sample solution and store at -20 to -80°C.
• Storage: Store under sterile conditions at -20 to -80°C immediately after receipt. It is recommended that the protein be aliquoted for optimal storage. Avoid freeze-thaw cycles.
• Related Product: Cd70-972M
• Official Symbol: Cd70
• Synonyms: CD70; CD70 antigen; CD27-L; CD27 ligand; Ki-24 antigen; tumor necrosis factor ligand superfamily member 7; tumor necrosis factor (ligand) superfamily, member 7; Cd27l; CD27LG; Tnfsf7

Gene Information

• Official Symbol: Cd70
• Synonyms: CD70; CD70 antigen; CD27-L; CD27 ligand; Ki-24 antigen; tumor necrosis factor ligand superfamily member 7; tumor necrosis factor (ligand) superfamily, member 7; Cd27l; CD27LG; Tnfsf7

Reviews

05/31/2021

Their collaboration, expertise, and customized solutions contribute to the successful execution of experiments, reliable data generation, and the advancement of scientific knowledge in the field.

04/23/2019

the manufacturer's support is crucial for researchers using CD70 protein in trials.

03/07/2017

These resources can enhance the efficiency and accuracy of experimental workflows and contribute to successful outcomes.

Q&As

What are some potential CD70-targeted therapies for cancer?

Antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T-cell therapies are being developed to target CD70 in cancer.

How can CD70-targeted therapies improve cancer treatment outcomes?

CD70-targeted therapies can enhance the body's immune response against cancer cells and potentially lead to more effective treatments.

In which hematological malignancies is CD70 expression frequently observed?

CD70 expression is often observed in Hodgkin's lymphoma and certain types of T-cell lymphomas.

Are there any challenges in developing CD70-targeted therapies for cancer?

Challenges include potential toxicities and finding the right balance to target CD70 effectively without harming normal immune functions.

Are there clinical trials involving CD70-targeted therapies for cancer treatment?

Yes, there are ongoing clinical trials exploring CD70-targeted therapies for various cancer types.